10x Genomics Inc. (NASDAQ:TXG) saw a surge in stock price to a new 52-week high after narrowing its net loss and surpassing revenue guidance for the third quarter, reaching $17.08 per share. Net loss decreased by 23% to $27.47 million, while revenue slightly declined to $149 million.

Although revenue dipped slightly due to lower instrument revenue, 10x Genomics Inc. (NASDAQ:TXG) beat its guidance. The company expects fourth-quarter revenue between $154 million and $158 million, reflecting steady performance drivers. CEO Serge Saxonov anticipates no significant changes in customer purchasing behavior.

Despite 10x Genomics’ positive performance, other AI stocks may offer better returns with less risk. Learn about a promising AI stock in our free report. For more insights, explore “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now.” No disclosures were made in this article.

Read more at Yahoo Finance: 10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat